Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
Dow
Moodys
Boehringer Ingelheim

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Ganitumab


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Ganitumab?

Ganitumab is an investigational drug.

There have been 15 clinical trials for Ganitumab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 8th 2014.

The most common disease conditions in clinical trials are Neoplasms, Colorectal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and NantCell, Inc.

There are twelve US patents protecting this investigational drug and two hundred and fifty-six international patents.

Recent Clinical Trials for Ganitumab
TitleSponsorPhase
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaNational Cancer Institute (NCI)Early Phase 1
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaM.D. Anderson Cancer CenterEarly Phase 1
Palbociclib + Ganitumab In Ewing Sarcoma1 Million 4 Anna FoundationPhase 2

See all Ganitumab clinical trials

Clinical Trial Summary for Ganitumab

Top disease conditions for Ganitumab
Top clinical trial sponsors for Ganitumab

See all Ganitumab clinical trials

US Patents for Ganitumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganitumab ⤷  Sign up for a Free Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) ⤷  Sign up for a Free Trial
Ganitumab ⤷  Sign up for a Free Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ⤷  Sign up for a Free Trial
Ganitumab ⤷  Sign up for a Free Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) ⤷  Sign up for a Free Trial
Ganitumab ⤷  Sign up for a Free Trial Curcuphenol compounds for increasing MHC-I expression CAVA HEALTHCARE INC. (CA) ⤷  Sign up for a Free Trial
Ganitumab ⤷  Sign up for a Free Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganitumab

Drugname Country Document Number Estimated Expiration Related US Patent
Ganitumab Canada CA2900764 2033-02-08 ⤷  Sign up for a Free Trial
Ganitumab European Patent Office EP2954056 2033-02-08 ⤷  Sign up for a Free Trial
Ganitumab Hong Kong HK1218930 2033-02-08 ⤷  Sign up for a Free Trial
Ganitumab Japan JP2016509014 2033-02-08 ⤷  Sign up for a Free Trial
Ganitumab World Intellectual Property Organization (WIPO) WO2014124326 2033-02-08 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
Dow
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.